Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
نویسندگان
چکیده
Background A wide range of response rates have been reported in HER2-positive gastric cancer (GC) patients treated with trastuzumab. Other HER2-targeted therapies for GC have yet to show efficacy in clinical trials. These findings raise question about the ability of standard HER2 diagnostics to accurately distinguish between GC patients who would and would not benefit from anti-HER2 therapies. Patients and methods GC patients (n = 237), including a subset from the Trastuzumab in GC (ToGA) trial were divided into three groups based on HER2 status and history of treatment with standard chemotherapy or chemotherapy plus trastuzumab. We applied mass spectrometry-based proteomic analysis to quantify HER2 protein expression in formalin-fixed tumor samples. Using HER2 expression as a continuous variable, we defined a predictive protein level cutoff to identify which patients would benefit from trastuzumab. We compared quantitated protein level with clinical outcome and HER2 status as determined by conventional HER2 diagnostics. Results Quantitative proteomics detected a 115-fold range of HER2 protein expression among patients diagnosed as HER2 positive by standard methods. A protein level of 1825 amol/µg was predicted to determine benefit from the addition of trastuzumab to chemotherapy. Trastuzumab treated patients with HER2 protein levels above this cutoff had twice the median overall survival (OS) of their counterparts below the cutoff (35.0 versus 17.5 months, P = 0.011). Conversely, trastuzumab-treated patients with HER2 levels below the cutoff had outcomes similar to HER2-positive patients treated with chemotherapy. (Progression-free survival = 7.0 versus 6.5 months: P = 0.504; OS = 17.5 versus 12.6 months: P = 0.520). HER2 levels were not prognostic for response to chemotherapy. Conclusions Proteomic analysis of HER2 expression demonstrated a quantitative cutoff that improves selection of GC patients for trastuzumab as compared with current diagnostic methods.
منابع مشابه
Effectiveness of trastuzumab as adjuvant therapy in patients with early stage breast cancer: A systematic review and meta-analysis
Background: Trastuzumab in combination with chemotherapy has long been established as a standard treatment for HER2-positive patients in early stage breast cancer (BC). The present study aimed at assessing the effectiveness of trastuzumab adjuvant therapy in early stage BC in overall survival (OS) and disease-free survival (DFS). Methods: A systematic review and meta-analysis was ...
متن کاملResistance to HER2-targeted therapy
Production and approval of trastuzumab (Herceptin®) for the treatment of metastatic breast cancer (MBC) was a millstone in antibody-based targeted therapy in the cancer treatment. However, despite the early success in the clinical trials, trastuzumab failed to appreciate the initial attraction due to development of resistance to the drug. The majority of patients who benefit from the drug...
متن کاملبررسی بیان گیرنده HER2 و HER1 در نمونه های آدنوکارسینوم پیشرفته موضعی معده و ارتباط آن با میزان بقاء بیماران
Background and purpose: Mortality rate from gastric cancer is growing in the world. Nowadays, in many cancers, between cancer development and changes in EGF receptor expression levels there is a very precise relationship. Perhaps one of the best known of these changes in gastric cancer is over expression of Her1 & 2 receptors. This study investigated the expression rate of these two receptors i...
متن کاملEvaluation of the Prognostic Value and TRIP13 gene Expression in Gastric Cancer
Introduction: Gastric cancer is a major public health issue worldwide. The factors that initiate cancer are not well understood, however aberrant expression of genes is associated with this cancer. TRIP13 plays pivotal roles in meiotic recombination, DNA repair, and cell cycle progression. An increasing body of evidence suggests that TRIP13 may possess functions other than meiosis and mitosis, ...
متن کاملTrastuzumab in the management of gastroesophageal cancer: patient selection and perspectives
The addition of trastuzumab to the treatment of a subset of patients with advanced gastric and gastroesophageal junction cancers showing HER2 positivity has been shown to confer clinical benefit; however, questions remain over the optimal methods for defining and selecting such patients. This review provides an overview of current standards for assessing HER2 positivity, the evolving treatment ...
متن کامل